Combined Treatment for Patients with Brain Metastases from Non-small Cell Lung Cancer with Whole Brain Radiotherapy (WBRT) and Gefitinib (GFT) or Temozolomide (TMZ). A Randomized M... von Pesce, G.A, Von Moos, R, D'Addario, G, Fischer, N, Caspar, C.B, Anchisi, S, Kotrubczik, N, Zouhair, A, Mayer, M, Stupp, R

Volltext

Renal safety profile of ibandronate 6mg infused over 15 or 60 min in breast cancer patients with bone metastases von Schütz, F, von Moos, R, Caspar, C.B, Angst, R, Inauen, R, Greil, R, Ziegler, J, Pecherstorfer, M

Volltext

1570P Outcome and prognostic factors of COVID-19 infection in cancer patients: Final results of SAKK 80/20 von Joerger, M., Metaxas, Y., Zaman, K., Michielin, O.A., Mach, N., Betticher, D., Schmitt, A.M., Cantoni, N., Caspar, C.B., Stettler, S., Malval, R., Pless, M., Britschgi, C., Renner, C., Koeberle, D., Schulz, J., Kopp, C., Hayoz, S., Stathis, A., von Moos, R.

Volltext

1867P Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents: A real-world cross-sectional study from Switzerland (SA... von Ribi, K., Thuerlimann, B.J.K., Schär, C., Dietrich, D., Cathomas, R., Zuerrer, U., Von Briel, T., Anchisi, S., Bohanes, P., Blum, V., von Burg, P., Mannhart, M., Caspar, C.B., von Moos, R., Mark, M.T.

Volltext

LBA80 Outcome and prognostic factors of SARS CoV-2 infection in cancer patients: A cross-sectional study (SAKK 80/20 CaSA) von Joerger, M., Metaxas, Y., Schmitt, A., Koeberle, D., Zaman, K., Betticher, D., Mach, N., Renner, C., Mark, M.T., Petrausch, U., Caspar, C.B., Britschgi, C., Taverna, C., Zenger, F., Mingrone, W., Schulz, J., Kopp, C., Hayoz, S., Stathis, A., von Moos, R.

Volltext

268P Anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple-negative, EGFR positive breast cancer: A multicenter single arm phase II trial [SAKK 24/14] von Wicki, A., Mamot, C., Hasler-Strub, U., Riniker, S., Li, Q., Holer, L., Baertschi, D., Zaman, K., von Moos, R., Dedes, K.J., Novak, U., Bodmer, A., Ritschard, R., Obermann, E., Ackermann, C.J., Membrez-Antonioli, V., Zuerrer, U., Caspar, C.B., Rochlitz, C., Winterhalder, R.C.

Volltext

345P Optimal dose of eribulin as first line treatment in elderly patients ≥ 70 years with advanced breast cancer: A multicenter phase II trial [SAKK 25/14] von Hasler-Strub, U., Mueller, A., Li, Q., Thuerlimann, B.J.K., Gerber, S., von Moos, R., Fehr, M., Rochlitz, C., Zaman, K., Aebi, S., Hochstrasser, A.M., Gick, U., Ribi, K., Baertschi, D., Greuter, S., Schreiber, A., Caspar, C.B., Trojan, A., Condorelli, R., Ruhstaller, T.

Volltext

Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study von von Moos, R., Caspar, C.B., Thürlimann, B., Angst, R., Inauen, R., Greil, R., Bergstrom, B., Schmieding, K., Pecherstorfer, M.

Volltext

R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial von Chamuleau, M.E.D., Stenner, F., Chitu, D.A., Novak, U., Minnema, M.C., Geerts, P., Stevens, W.B.C., Zenz, T., Imhoff, G.W.V., Wu, K.L., Demandt, A.M.P., Kersten, M.J., Terpstra, W.E., Tick, L.W., Deeren, D., Neste, E.V., Gregor, M., Veelken, H., Boehmer, L.H., Caspar, C.B., Mutsaers, P., Refos, J.M., Sewsaran, R., Fu, L.P., Seefat, R.L., Groot, C.A.U.D., Dirnhofer, S., Brand, M.V., Jong, D. de, Nijland, M., Lugtenburg, P.

Volltext bestellen